共 50 条
Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
被引:0
|作者:
Vega, Luis
[1
]
Simian, Daniela
[1
]
Gajardo, Abraham I.
[2
]
Salinas, Marcelo
[1
]
Urra, Andrea
[1
]
Cattaneo, Maximo
[1
]
Pino, Rosario
[1
]
Roblero, Juan P.
[1
]
Urzua, Alvaro
[1
]
Rojas, Katherine
[1
]
Poniachik, Jaime
[1
]
机构:
[1] Hosp Clin Univ Chile, Med Dept, Gastroenterol Sect, Santiago, Chile
[2] Hosp Clin Univ Chile, Med Dept, Crit Patient Care Unit, Santiago, Chile
关键词:
Metabolic dysfunction-associated fatty liver disease;
Liver fibrosis;
Coronary heart disease;
D O I:
10.1016/j.aohep.2024.101511
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Introduction and Objectives: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at an increased cardiovascular risk. On the contrary, non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with coronary heart disease (CHD). However, it is not known whether patients with significant CHD show a higher frequency of liver fibrosis. This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether coronary stenosis is significantly associated with MASLD and fibrosis. Patients and Methods: This observational and analytical study included adult patients without any known liver disease who underwent coronary angiography for suspected coronary artery disease (Jul 2021-Jul 2022). The presence of significant CHD (> 50% stenosis of at least one coronary artery) was determined. Liver elastography (FibroScan (R)) was performed up to 6 months after the coronary angiographic study to determine liver fibrosis, a measurement of liver stiffness (> 6.5 Kpa). Fisher's test, Mann-Whitney U test, and logistic regression models were used (p < 0.05). Results: The study included 113 patients (76% men, average age: 63 years [standard deviation: 9.9]), of which 72% presented with significant CHD. The prevalence rate of MASLD was 52%. Liver fibrosis was present in 12% of the patients and all patients in the significant CHD group (p = 0.007). An increase in the number of vessels with significant CHD increased the probability of liver fibrosis (odds ratio, 1.79; 95% confidence interval, 1.06-3.04; p = 0.029). Conclusions: MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies. (c) 2024 Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of Fundaci & oacute;n Cl & iacute;nica M & eacute;dica Sur, A.C. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:5
相关论文